GlassScriptPhysician profile
Rainer A Khetan
NPI 1225059256
$7,695.84
in general payments reported to CMS, 2019-2025
52 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $594 · 2021: $1,286 · 2022: $1,095 · 2023: $1,183 · 2024: $1,345 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $975.47 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $585.16 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $576.28 | 2021-2025 | |
| Novo Nordisk INC | $567.74 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $553.31 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $486.21 | 2019-2025 | |
| Amarin Pharma, INC. | $480.63 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.02 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $324.71 | 2019-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $292.58 | 2019-2024 | Eliquis, Camzyos |
| Mylan Specialty L.P. | $194.87 | 2021-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $163.63 | 2020-2025 | Saphnelo, Airsupra, Breztri |
| Lundbeck LLC | $159.83 | 2022-2023 | Vyepti |
| Sumitomo Pharma America, INC. | $153.04 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $135.00 | 2019-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rainer Khetan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.